Madrigal Pharmaceuticals (MDGL) is back in focus after publishing a secondary MAESTRO NASH analysis in the Journal of Hepatology, showing Rezdiffra efficacy across common genetic risk variants in metabolic dysfunction associated steatohepatitis.

The latest journal publication lands after a choppy stretch for Madrigal Pharmaceuticals, with the share price down 14.8% over the past 30 days and 22.5% year to date, even as total shareholder return over five years is up almost 5x. This suggests long term momentum remains intact while near term sentiment reacts to shifting expectations around Rezdiffra and the broader MASH opportunity.

Scan beyond Madrigal Pharmaceuticals and look for other treatment-focused biotechs that could be approaching…